Ozempic vs Trelegy Ellipta
Side-by-side drug price comparison from Medicare Part D data
Verdict
Trelegy Ellipta costs 45% less per claim than Ozempic ($380.00 vs $685.00). Neither drug has a generic alternative available. Total Medicare spending: Ozempic at $5.0B vs Trelegy Ellipta at $2.9B.
| Metric | Ozempic | Trelegy Ellipta |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $685 | $380* |
| Total Medicare Spending Total Medicare Part D spending on this drug | $5.0B | $2.9B |
| Total Claims | 7,240,000 | 7,560,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | 72.5% | 19.8%* |
| Generic Available | No | No |
| Condition | Diabetes | Asthma/COPD |
| Total Beneficiaries | 1,180,000 | 865,000 |
Trelegy Ellipta costs 45% less per claim than Ozempic ($380.00 vs $685.00). Neither drug has a generic alternative available. Total Medicare spending: Ozempic at $5.0B vs Trelegy Ellipta at $2.9B.
Explore More
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both Ozempic and Trelegy Ellipta. What follows is the interpretation — which specific axes carry the most weight for Ozempic versus Trelegy Ellipta, and which differences are large enough to influence a real decision.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.